In pur­suit of a block­buster, Am­gen and As­traZeneca score pri­or­i­ty re­view for asth­ma drug teze­pelum­ab

Am­gen and As­traZeneca are one big step clos­er to re­al­iz­ing their block­buster dreams for teze­pelum­ab af­ter the FDA grant­ed a pri­or­i­ty re­view for the asth­ma drug.

De­spite the chal­lenge of bat­tling Re­gen­eron and Sanofi’s Dupix­ent, teze­pelum­ab has been pegged for peak sales of $2.5 bil­lion. With As­traZeneca lead­ing de­vel­op­ment, Am­gen spear­head­ing man­u­fac­tur­ing and both shar­ing com­mer­cial­iza­tion re­spon­si­bil­i­ties, the two phar­ma gi­ants have been vo­cal about their op­ti­mism.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER